MentalHealthDaily

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …

30+ New Antidepressants (2018): Drugs In Clinical Trials

by GLOOM

Research suggests that upwards of 16 million American adults (6.7% of the adult population) are afflicted with major depressive disorder (MDD), a neuropsychiatric condition characterized by overwhelming sadness, behavioral changes, sleep disturbances, and cognitive deficits. As of current, depression is the leading cause of disability in the United States among individuals between the ages of …

20 New Antidepressants In The Pipeline (2015): Drugs In Clinical Trials

by GLOOM

For individuals in the United States between the age of 15 and 44, major depression is the leading cause of disability. Major depression is often a heritable condition, caused by maladaptive genes getting transferred across generations. That said, not everyone diagnosed with major depressive disorder inherited the condition from ancestors or should be blaming their …

5 New NMDA Receptor (Glutamate) Modulators For Depression

by GLOOM

Scientists and mental health researchers have long been collecting evidence to discover what causes depression. Their goal is to find a specific neurotransmitter or system that could be targeted to develop a new class of antidepressant medication that would be more effective for the masses, result in less side effects, and be considered safe. While …